Option chain shows key data for SAB Biotherapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for SAB Biotherapeutics.

SAB Biotherapeutics (NASDAQ:SABS) Stock, Option Chain

SAB BIOTHERAPEUTICS INC

SAB Biotherapeutics

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

SABS

Biotech

News

Health Care

Movers

Trading Ideas

General

SAB BIO&#39;s SAB-142 Phase 1 trial data supports its safety and pharmacodynamic activity, paving the way for a Phase 2b trial in T1D in 2025.

Why Is SAB BIO Stock Trading Lower On Tuesday?

Gold

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

Brighthouse Financial, Inc. - Common Stock

LPTX

SLXN

STSS

Gold Gains 1%; Boeing Shares Rise Following Q4 Results

Nasdaq index

Nasdaq Surges More Than 300 Points; Lockheed Martin Shares Dip After Q4 Results

SAB Biotherapeutics Inc

Press Releases

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

Analyst Ratings

SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

SAB BIO to Participate in Upcoming Investor Conferences

SABSW

Aprea Therapeutics

BioCardia

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Elevation Oncology

Ernexa Therapeutics

GlycoMimetics

Geovax Labs

HCW Biologics

HOOKIPA Pharma

Imunon

IN8bio

Kairos Pharma

Leap Therapeutics

Moleculin Biotech

MEI Pharma

Marker Therapeutics

MetaVia

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NextCure

BiomX

Spruce Biosciences

Synlogic

Chardan Capital

HC Wainwright & Co.

Craig-Hallum

Oppenheimer

Brookline Capital

Comments

SAB Biotherapeutics

SAB Biotherapeutics (SABS) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga